Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C31H34ClN5O4 |
| Molecular Weight | 576.086 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)N(O)CCC#CC1=CC=C(OCCN2CCN(CC2)[C@H](C3=CC=CC=C3)C4=CC=C(Cl)C=C4)C(=C1)C(N)=O
InChI
InChIKey=KHVLZYHEWIBDOU-GDLZYMKVSA-N
InChI=1S/C31H34ClN5O4/c32-26-12-10-25(11-13-26)29(24-7-2-1-3-8-24)36-18-16-35(17-19-36)20-21-41-28-14-9-23(22-27(28)30(33)38)6-4-5-15-37(40)31(34)39/h1-3,7-14,22,29,40H,5,15-21H2,(H2,33,38)(H2,34,39)/t29-/m1/s1
| Molecular Formula | C31H34ClN5O4 |
| Molecular Weight | 576.086 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:28:27 GMT 2023
by
admin
on
Sat Dec 16 11:28:27 GMT 2023
|
| Record UNII |
Q5WMS52P89
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
299460-62-1
Created by
admin on Sat Dec 16 11:28:27 GMT 2023 , Edited by admin on Sat Dec 16 11:28:27 GMT 2023
|
PRIMARY | |||
|
Q5WMS52P89
Created by
admin on Sat Dec 16 11:28:27 GMT 2023 , Edited by admin on Sat Dec 16 11:28:27 GMT 2023
|
PRIMARY | |||
|
9894415
Created by
admin on Sat Dec 16 11:28:27 GMT 2023 , Edited by admin on Sat Dec 16 11:28:27 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Chemical synthesis of compound.
|
||
|
SALT/SOLVATE -> PARENT |
Chemical synthesis of compound.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY | |||
|
ACTIVE MOIETY |
Compounds and methods for treatment of asthma, allergy and inflammatory disorders. Chemical synthesis of ucb-35440.
|
||
|
ACTIVE MOIETY |
Single oral doses of ucb 35440 (10 mg/kg in 0.5% methylcellulose suspension) at 1, 2, 6 or 24 h pre-histamine challenge produced minimal inhibition of histamine-induced extravasation in the dermis. However, when ucb 35440 (10 mg/kg in a 0.5% methylcellulose suspension) was orally administered 24 and 2 h prior to dermal histamine challenge, significant inhibition of extravasation was observed. Similar inhibition of histamine-induced extravasation was observed when animals were orally dosed twice a day (AM and PM 10 mg/kg in a 0.5% methylcellulose suspension) for 5.5 days prior to dermal histamine challenge. Collectively, these results suggest that ucb 35440 may represent an important therapeutic class for the treatment of dermatologic inflammatory conditions.
|
||
|
ACTIVE MOIETY |
Class: Antiallergic, Antiasthmatic, Piperazine; Mechanism of Action: 5-lipoxygenase inhibitor, Histamine H1 receptor antagonist; Highest Development Phase: Suspended for Allergic rhinitis and Asthma; Most Recent Events: 05 Aug 2004 Suspended - Phase-II for Asthma (PO), 05 Aug 2004 Suspended - Phase-I for Allergic rhinitis (PO)
|
